Icagen have initiated a Phase II clinical trial of KCa3.1 potassium ion channel blocker senicapoc in patients with allergic asthma.
Filed under: Uncategorized | Tagged: Icagen, KCa3.1, phase II, Senicapoc | Leave a Comment »
Icagen being Phase II trial of Senicapoc in Allergic Asthma
Posted on October 14, 2008 by crimsoncanary
Senicapoc blocks KCa3.1 currents in mast cells
Posted on September 23, 2008 by crimsoncanary
Data presented at the 15th International Inflammation Research Association Conference show Icagen’s KCa3.1 potassium ion channel inhibitor senicapoc to potently block KCa3.1 potassium currents in isolated human lung mast cells and reduce the migration of these cells when exposed to an inflammatory stimulus.
Filed under: Uncategorized | Tagged: Icagen, K Channel, KCa3.1, Senicapoc | Leave a Comment »
Icagen completes Phase I trial of KCa3.1 potassium ion channel senicapoc
Posted on July 10, 2008 by crimsoncanary
Icagen have completed a Phase I trial of KCa3.1 potassium ion channel senicapoc which has potential in the treatment of asthma. The drug was well tolerated at all doses tested and in preliminary analyses
Filed under: Potassium Channel | Tagged: ICA-17043, ICA17043, Icagen, K Channel, KCa3.1, Potassium Channel, Senicapoc | Leave a Comment »
Icagen report on Ion Channel Progress
Posted on May 8, 2008 by crimsoncanary
ICA-105665 KCNQ channel opener for epilepsy – Single ascending dose Phase I trial completed; multiple ascending dose Phase I initiated
Senicapoc for Asthma – Phase I trial initiated
Na and Ca channel Pain Program – Leads identified
Phase II trials for both projects expected in the second half of 2008
Filed under: Calcium Channel, Ion Channel, Potassium Channel, Sodium channel | Tagged: ca channel, Calcium Channel, ICA-17043, ICA17043, Icagen, Ion Channel, K Channel, KCNQ, na channel, Potassium Channel, Senicapoc, Sodium channel | Leave a Comment »
